These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38221577)

  • 1. Silent battles: immune responses in asymptomatic SARS-CoV-2 infection.
    Le Bert N; Samandari T
    Cell Mol Immunol; 2024 Feb; 21(2):159-170. PubMed ID: 38221577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.
    Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P
    Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
    Carsetti R; Zaffina S; Piano Mortari E; Terreri S; Corrente F; Capponi C; Palomba P; Mirabella M; Cascioli S; Palange P; Cuccaro I; Milito C; Zumla A; Maeurer M; Camisa V; Vinci MR; Santoro A; Cimini E; Marchioni L; Nicastri E; Palmieri F; Agrati C; Ippolito G; Porzio O; Concato C; Onetti Muda A; Raponi M; Quintarelli C; Quinti I; Locatelli F
    Front Immunol; 2020; 11():610300. PubMed ID: 33391280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of Innate and Adaptive Immune Responses in Asymptomatic SARS-CoV-2 Infection with Delayed Viral Clearance.
    Cao S; Zhang Q; Song L; Xiao M; Chen Y; Wang D; Li M; Hu J; Lin L; Zheng Y; Zhou K; Ye S; Zhou J; Zhou YN; Cui J; Wang J; Sun J; Tao J; Chen Z; Chen R; Zhou P; Shi Z; Wei S; Zhao L; Wang H; Tong X; Li X; Men D; Hou B; Zhang XE
    Int J Biol Sci; 2022; 18(12):4648-4657. PubMed ID: 35874943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
    Long QX; Tang XJ; Shi QL; Li Q; Deng HJ; Yuan J; Hu JL; Xu W; Zhang Y; Lv FJ; Su K; Zhang F; Gong J; Wu B; Liu XM; Li JJ; Qiu JF; Chen J; Huang AL
    Nat Med; 2020 Aug; 26(8):1200-1204. PubMed ID: 32555424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
    Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort.
    Tegeler CM; Bilich T; Maringer Y; Salih HR; Walz JS; Nelde A; Heitmann JS
    Int J Infect Dis; 2022 Jul; 120():187-195. PubMed ID: 35429640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.
    Paniskaki K; Goretzki S; Anft M; Konik MJ; Lechtenberg K; Vogl M; Meister TL; Pfaender S; Zettler M; Jäger J; Dolff S; Westhoff TH; Rohn H; Felderhoff-Mueser U; Stervbo U; Witzke O; Dohna-Schwake C; Babel N
    BMC Infect Dis; 2023 Nov; 23(1):818. PubMed ID: 37993788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity.
    Altmann DM; Reynolds CJ; Joy G; Otter AD; Gibbons JM; Pade C; Swadling L; Maini MK; Brooks T; Semper A; McKnight Á; Noursadeghi M; Manisty C; Treibel TA; Moon JC; ; Boyton RJ
    Nat Commun; 2023 Aug; 14(1):5139. PubMed ID: 37612310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.
    Vangeti S; Periasamy S; Sun P; Balinsky CA; Mahajan AS; Kuzmina NA; Soares-Schanoski A; Cooper E; Beckett C; Marayag J; Marrone A; Nunez E; Ge Y; Porter CK; Goforth CW; Lizewski SE; Lizewski R; Jani V; Sugiharto VA; Schilling M; Yu XB; Marjanovic N; George MC; Bukreyev A; Sealfon SC; Letizia AG; Ramos I
    Microbiol Spectr; 2022 Dec; 10(6):e0183722. PubMed ID: 36374040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.
    Wu J; Liang BY; Fang YH; Wang H; Yang XL; Shen S; Chen LK; Li SM; Lu SH; Xiang TD; Liu J; Le-Trilling VTK; Lu MJ; Yang DL; Deng F; Dittmer U; Trilling M; Zheng X
    Front Immunol; 2021; 12():722027. PubMed ID: 34489971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic
    Sfikakis PP; Verrou KM; Ampatziadis-Michailidis G; Tsitsilonis O; Paraskevis D; Kastritis E; Lianidou E; Moutsatsou P; Terpos E; Trougakos I; Chini V; Manoloukos M; Moulos P; Pavlopoulos GA; Kollias G; Hatzis P; Dimopoulos MA
    Front Immunol; 2021; 12():746203. PubMed ID: 34675930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Prospective Seroconversion and PCR Data of Selected Cohorts Indicate a High Rate of Subclinical SARS-CoV-2 Infections-an Open Observational Study in Lower Saxony, Germany.
    Jonczyk R; Stanislawski N; Seiler LK; Blume H; Heiden S; Lucas H; Sarikouch S; Pott PC; Stiesch M; Hauß C; Saletti G; González-Hernández M; Kaiser FK; Rimmelzwaan G; Osterhaus A; Blume C
    Microbiol Spectr; 2022 Feb; 10(1):e0151221. PubMed ID: 35171028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.
    Reynolds CJ; Swadling L; Gibbons JM; Pade C; Jensen MP; Diniz MO; Schmidt NM; Butler DK; Amin OE; Bailey SNL; Murray SM; Pieper FP; Taylor S; Jones J; Jones M; Lee WJ; Rosenheim J; Chandran A; Joy G; Di Genova C; Temperton N; Lambourne J; Cutino-Moguel T; Andiapen M; Fontana M; Smit A; Semper A; O'Brien B; Chain B; Brooks T; Manisty C; Treibel T; Moon JC; ; Noursadeghi M; ; Altmann DM; Maini MK; McKnight Á; Boyton RJ
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33361161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
    Rokni M; Ghasemi V; Tavakoli Z
    Rev Med Virol; 2020 May; 30(3):e2107. PubMed ID: 32267987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.